Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT1 | P54687 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CUL4A | Q13619 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30151887 | 1.00 | BCAT1 (0.39) | BCAT1TSHRTRPV4LMNADYRK1A | |
| SCHEMBL832 | 0.83 | TSHR (0.46) | TSHRLMNADYRK1AESR2CA1 | |
| SCHEMBL16958809 | 0.77 | CES2 (0.30) | — | |
| SCHEMBL31032883 | 0.76 | DYRK1A (0.47) | TSHRLMNADYRK1AESR2CA1 | |
| SCHEMBL30443847 | 0.76 | BCAT1 (0.49) | BCAT1TSHRTRPV4CA1CA2 | |
| SCHEMBL3386194 | 0.76 | DYRK1A (0.47) | TSHRLMNADYRK1AESR2CA1 | |
| SCHEMBL158537 | 0.76 | BCAT1 (0.49) | BCAT1TSHRTRPV4CA1CA2 | |
| Water SCHEMBL28049227 | 0.76 | BCAT1 (0.49) | BCAT1TSHRTRPV4CA1CA2 | |
| SCHEMBL100446 | 0.75 | — | — | |
| SCHEMBL30489137 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 276 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118027031-A | Carbonyl ring-closed arylamine fluorescent compound with narrow band emission, and preparation method and application thereof | 广东工业大学 | 2024-05-14 | — | — | CN | claimed |
| CN-115745974-A | Chiral near ultraviolet organic electroluminescent material, preparation method thereof and application thereof in CP-OLED | 华南理工大学 | 2023-03-07 | — | — | CN | claimed |
| EP-3688116-B1 | ORGANIC MOLECULES, IN PARTICULAR FOR USE IN OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2022-04-06 | — | — | EP | claimed |
| EP-3672956-B1 | ORGANIC TRIAZINE CONTAINING MOLECULES, IN PARTICULAR FOR USE IN OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2021-06-02 | — | — | EP | claimed |
| US-10919880-B2 | Organic molecules, in particular for use in optoelectronic devices | CYNORA GMBH (DE) | 2021-02-16 | — | — | US | claimed |
| EP-3688116-A1 | ORGANIC MOLECULES, IN PARTICULAR FOR USE IN OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2020-08-05 | — | — | EP | claimed |
| EP-3672956-A1 | ORGANIC TRIAZINE CONTAINING MOLECULES, IN PARTICULAR FOR USE IN OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2020-07-01 | — | — | EP | claimed |
| EP-3266772-B1 | ORGANIC MOLECULES, IN PARTICULAR FOR USE IN OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2019-04-24 | — | — | EP | claimed |
| WO-2019063288-A1 | ORGANIC MOLECULES, IN PARTICULAR FOR USE IN OPTOELCTRONIC DEVICES | CYNORA GMBH (DE) | 2019-04-04 | — | — | WO | claimed |
| CN-109553567-A | Organic molecule, especially for the organic molecule in opto-electronic device | 辛诺拉有限公司 | 2019-04-02 | — | — | CN | claimed |
| CN-109422674-A | Organic molecule is especially used for the organic molecule of opto-electronic device | 辛诺拉有限公司 | 2019-03-05 | — | — | CN | claimed |
| WO-2019038448-A1 | ORGANIC TRIAZINE CONTAINING MOLECULES, IN PARTICULAR FOR USE IN OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2019-02-28 | — | — | WO | claimed |
| EP-3433239-B1 | SMALL MOLECULE INHIBITORS OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) | 2026-05-27 | — | — | EP | disclosed |
| CN-117024411-B | Isoquinoline as HPK1 inhibitor | 豪夫迈·罗氏有限公司 | 2026-05-19 | — | — | CN | disclosed |
| EP-4720044-A1 | AROMATIC AMIDES AND CONJUGATES THEREOF AS BINDERS TO TEAD | Beactica Therapeutics AB (SE) | 2026-04-08 | — | — | EP | disclosed |
| EP-4121421-B1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | NOVARTIS AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20020193385-A1 | Imidazo-pyrimidine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2002-12-19 | — | — | US | disclosed |
| WO-2002074772-A1 | IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2002-09-26 | — | — | WO | disclosed |
| WO-2002074773-A1 | IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2002-09-26 | — | — | WO | disclosed |
| WO-2002038568-A1 | IMIDAZO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2002-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193385-A1 | Imidazo-pyrimidine derivatives as ligands for gaba receptors | GABRA3, GABRA1, GABRA2 | BCAT1 193/4885TSHR 240/4885TRPV4 1861/4885 |
| US-10919880-B2 | Organic molecules, in particular for use in optoelectronic devices | OCIAD1, OCIAD2, POU2F1 | BCAT1 4099/4885TSHR 3378/4885TRPV4 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.